Claims for Patent: 6,346,385

Summary for Patent: 6,346,385

Title:	Analysis of predisposition based on human airway trypsin protease gene polymorphism
Abstract:	A method for predicting the constitution susceptible to the onset of specific diseases in individual humans, for example, respiratory diseases such as chronic obstructive pulmonary diseases, sinobronchial syndrome, pulmonary emphysema, diffuse panbronchiolitis or bronchiectasis, effects of treatment on patients or prognosis of the treatment by analyzing the genetic polymorphisms of a human trypsin-like enzyme of the respiratory tract.
Inventor(s):	Eguchi; Hiroshi (Tokyo, JP), Yamaoka; Kazuyoshi (Tokyo, JP), Masuda; Kenichi (Tokyo, JP), Yasuoka; Susumu (Tokushima, JP)
Assignee:	Teijin Limited (Osaka, JP)
Application Number:	09/581,617
Patent Claims:	1. A method for predicting susceptibility to the onset of an obstructive pulmonary disease in a human, comprising: (a) amplifying intron C of a human trypsin-like enzyme gene to produce a 3.4 kb amplification product that comprises intron C; (b) digesting the amplification product of step (a) with restriction endonuclease BstUI; and (c) detecting the presence of a 3.4 kb undigested amplification product as indicative of a BB genotype, wherein the presence of said genotype is indicative of susceptibility to onset of said obstructive pulmonary disease. 2. The method of claim 1 wherein the obstructive pulmonary disease is diffuse panbronchiolitis, bronchiectasis, or pulmonary emphysema. 3. The method of claim 1, wherein a primer pair comprising SEQ ID NO: 11 and SEQ ID NO: 12 is used in amplifying step (a). 4. A method for predicting susceptibility to the onset of an obstructive pulmonary disease in a human, comprising: (a) amplifying intron C of a human trypsin-like enzyme gene to produce a 3.4 kb amplification product that comprises intron C; (b) digesting the amplification product of step (a) with restriction endonuclease BstUI and separately digesting the amplification product of step (a) with restriction endonuclease MboI; and (c) detecting the presence of a 3.4 kb undigested amplification product from the BstUI digestion and a 1.05 kb restriction fragment from the MboI digestion as indicative of a Bm haplotype, wherein the presence of said haplotype is indicative of susceptibility to onset of said obstructive pulmonary disease. 5. The method of claim 4 wherein the obstructive pulmonary disease is diffuse panbronchiolitis, bronchiectasis, or pulmonary emphysema. 6. The method of claim 4, wherein a primer pair comprising SEQ ID NO: 11 and SEQ ID NO: 12 is used in amplifying step (a). 7. A nucleic acid fragment of an intron of a human trypsin-like enzyme gene wherein said nucleic acid fragment is prepared by a method consisting essentially of amplifying an intron of a human trypsin-like enzyme gene with a primer pair comprising SEQ ID NO: 11 and SEQ ID NO: 12. 8. A nucleic acid fragment of an intron of a human trypsin-like enzyme gene comprising SEQ ID NO: 5 or SEQ ID NO: 6. 9. A nucleic acid fragment of an intron of a human trypsin-like enzyme gene comprising SEQ ID NO: 17.

Details for Patent 6,346,385

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-12-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-12-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-12-16